Skye Bioscience, Inc. Increase (Decrease) in Other Accrued Liabilities
Skye Bioscience, Inc. (SKYE) reported Increase (Decrease) in Other Accrued Liabilities of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2025-05-08
- Skye Bioscience, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Skye Bioscience, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2024-03-31 was $75.07K.
- Skye Bioscience, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2023-09-30 was $60.27K, a 36.72% increase year-over-year.
- Skye Bioscience, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Skye Bioscience, Inc. increase (decrease) in other accrued liabilities for fiscal 2022 was -$159.10K, a 221.61% decline from fiscal 2021.
- Skye Bioscience, Inc. increase (decrease) in other accrued liabilities for fiscal 2021 was $130.82K, a 196.74% increase from fiscal 2020.
- Skye Bioscience, Inc. increase (decrease) in other accrued liabilities for fiscal 2020 was $44.09K.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2024-03-31 | $75.07K 10-Q · filed 2025-05-08 | |||
| 2023-09-30 | $60.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $60.27K derived: sum of 2 quarters · filed 2023-11-14 | $60.27K 10-Q · filed 2023-11-14 | -$229.65K derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | -$289.92K derived: sum of 3 quarters · filed 2023-08-07 | -$245.83K derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-12 | -$289.92K derived: sum of 2 quarters · filed 2023-05-12 | -$245.83K derived: sum of 3 quarters · filed 2023-11-14 | -$202.22K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | -$289.92K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$245.83K derived: sum of 2 quarters · filed 2023-11-14 | -$202.22K derived: sum of 3 quarters · filed 2023-11-14 | -$159.10K 10-K · filed 2023-03-31 |
| 2022-09-30 | $44.09K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $87.69K derived: sum of 2 quarters · filed 2023-11-14 | $130.82K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $43.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $86.74K 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $43.13K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $130.82K 10-K · filed 2023-03-31 | |||
| 2020-12-31 | $44.09K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |